• Suzanne E Lapi, Peter J H Scott, Andrew M Scott, Albert D Windhorst, Brian M Zeglis, May Abdel-Wahab, Richard P Baum, John M Buatti, Francesco Giammarile, Ana P Kiess, Amirreza Jalilian, Peter Knoll, Aruna Korde, Jolanta Kunikowska, LeeSze TingSTDepartment of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Departm, Diana Paez, Jean-Luc Urbain, Jingjing Zhang, and Jason S Lewis.
• Departments of Radiology and Chemistry, O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, AL, USA.
• Lancet Oncol. 2024 Jun 1; 25 (6): e236e249e236-e249.

AbstractThis paper is the first of a Series on theranostics that summarises the current landscape of the radiopharmaceutical sciences as they pertain to oncology. In this Series paper, we describe exciting developments in radiochemistry and the production of radionuclides, the development and translation of theranostics, and the application of artificial intelligence to our field. These developments are catalysing growth in the use of radiopharmaceuticals to the benefit of patients worldwide. We also highlight some of the key issues to be addressed in the coming years to realise the full potential of radiopharmaceuticals to treat cancer.Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.

8 keywords...

hide…